[go: up one dir, main page]

SK281803B6 - Orálny entericky potiahnutý prípravok, ktorý obsahuje magnéziovú soľ omeprazolu, a spôsob jeho výroby - Google Patents

Orálny entericky potiahnutý prípravok, ktorý obsahuje magnéziovú soľ omeprazolu, a spôsob jeho výroby

Info

Publication number
SK281803B6
SK281803B6 SK1660-96A SK166096A SK281803B6 SK 281803 B6 SK281803 B6 SK 281803B6 SK 166096 A SK166096 A SK 166096A SK 281803 B6 SK281803 B6 SK 281803B6
Authority
SK
Slovakia
Prior art keywords
omeprazole
nuclear material
production
magnesium salt
preparation containing
Prior art date
Application number
SK1660-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK166096A3 (en
Inventor
Siv Inga Bengtsson
Kurt Ingmar LÖVGREN
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of SK166096A3 publication Critical patent/SK166096A3/sk
Publication of SK281803B6 publication Critical patent/SK281803B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SK1660-96A 1994-07-08 1995-07-03 Orálny entericky potiahnutý prípravok, ktorý obsahuje magnéziovú soľ omeprazolu, a spôsob jeho výroby SK281803B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31320894A 1994-07-08 1994-07-08
SE9400679 1994-07-08
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Publications (2)

Publication Number Publication Date
SK166096A3 SK166096A3 (en) 1997-09-10
SK281803B6 true SK281803B6 (sk) 2001-08-06

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1660-96A SK281803B6 (sk) 1994-07-08 1995-07-03 Orálny entericky potiahnutý prípravok, ktorý obsahuje magnéziovú soľ omeprazolu, a spôsob jeho výroby

Country Status (15)

Country Link
EP (1) EP0768872A1 (is)
KR (1) KR970704426A (is)
BR (1) BR9508261A (is)
CA (1) CA2193681A1 (is)
CZ (1) CZ379596A3 (is)
EE (1) EE03378B1 (is)
FI (1) FI970058A0 (is)
HU (1) HUT78132A (is)
IS (1) IS4398A (is)
MX (1) MX9700152A (is)
NO (1) NO970036D0 (is)
NZ (1) NZ289958A (is)
PL (1) PL181265B1 (is)
SK (1) SK281803B6 (is)
WO (1) WO1996001622A1 (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
AU3762801A (en) * 2000-03-09 2001-09-17 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1552833B1 (en) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006002077A2 (en) * 2004-06-15 2006-01-05 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of benzimidazole compounds
CN105106168B (zh) * 2015-08-19 2018-03-06 德州德药制药有限公司 一种埃索美拉唑镁肠胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
EE03378B1 (et) 2001-04-16
EE9700014A (et) 1997-06-16
CZ379596A3 (en) 1997-08-13
MX9700152A (es) 1997-04-30
NO970036L (no) 1997-01-06
IS4398A (is) 1996-12-17
KR970704426A (ko) 1997-09-06
SK166096A3 (en) 1997-09-10
AU2994795A (en) 1996-02-09
CA2193681A1 (en) 1996-01-25
EP0768872A1 (en) 1997-04-23
NZ289958A (en) 1998-09-24
FI970058L (fi) 1997-01-07
FI970058A7 (fi) 1997-01-07
PL181265B1 (pl) 2001-06-29
HU9700039D0 (en) 1997-02-28
FI970058A0 (fi) 1997-01-07
NO970036D0 (no) 1997-01-06
AU695723B2 (en) 1998-08-20
BR9508261A (pt) 1997-12-23
PL318464A1 (en) 1997-06-09
WO1996001622A8 (en) 1999-12-23
HUT78132A (hu) 2000-06-28
WO1996001622A1 (en) 1996-01-25

Similar Documents

Publication Publication Date Title
SK281803B6 (sk) Orálny entericky potiahnutý prípravok, ktorý obsahuje magnéziovú soľ omeprazolu, a spôsob jeho výroby
FI921156A7 (fi) Paisuva, tulenkestävä päällyste, tulenkestävä materiaali ja menetelmä tulenkestävän materiaalin valmistamiseksi
DE3874836D1 (de) Waermehaertende pulvrige beschichtungszusammensetzung.
GR3024043T3 (en) Antifouling coating composition.
DE59203191D1 (de) Bauteilsatz zur Herstellung einer Verpackung.
ATE219165T1 (de) Film- oder schicht-abscheidung und pulver herstellung
AU8119687A (en) Multiple-layer, cook-in film
FI875153A7 (fi) Menetelmä kerrosten, kuten alustoilla olevien pintakerrosten paksuuden säätämiseksi ja/tai mittaamiseksi.
CA2054257A1 (en) A method of providing anti-oxidation protection for a composite material containing carbon, and a material protected thereby
MX9203168A (es) Substrato provisto de multiples capas, procedimiento para la formacion de dichas capas y composicion de revestimiento.
IT8420664A0 (it) Procedimento per preparare, una polvere finemente divisa scelta dal gruppo costituito da polvere di diboruro di titanio e polvere di diboruro di zirconio.
AU6333299A (en) High luster, flexible multilayered film with a polyamide outer layer containing nanodispersed filling material and utilization of said film for packaging foodstuffs
GR3015104T3 (en) Antifouling coating compositions.
DE68913130D1 (de) Pulverbeschichtungszusammensetzung.
FI99205B (fi) -olefiinien polymerointiin käyttökelpoinen kokatalyyttinen valmiste, sitä sisältävä katalyyttinen systeemi ja polymerointimenetelmä
MX9204272A (es) Composiciones para revestimientos en polvo termoestables.
NO163320C (no) Anordning for alternativt en- eller tosidig bestrykning av en loepende papirbane, og fremgangsmaate for anvendelse avanordningen.
FI943082A7 (fi) Isoforonia sisältämätön päällystyskoostumus, joka sisältää fluorihiili vetyä
UA37254C2 (uk) Багатошаровий папір
JPS5316735A (en) Manufacture of fireproof coating compounds
JPS527587A (en) Ship stern tube seal liner
JPS5250336A (en) Method for coating with synthetic resin
JPS52119645A (en) Fireproof tape
JPS5426827A (en) Antifouling coating composition
JPS5343736A (en) Coating method